Nieto C, Ramis J, Conte L, Fernández J M, Forn J
Research Centre, J. Uriach and Cia, S.A., Barcelona, Spain.
J Chromatogr B Biomed Appl. 1994 Nov 18;661(2):319-25. doi: 10.1016/0378-4347(94)00348-3.
A fully automated reversed-phase HPLC method for pharmacokinetic studies was developed for the determination in plasma samples of 1,2-dihydro-4-(1,2-dihydro-2-oxo-1-pyridyl)-2,2-dimethyl-1-oxonaphtha lene-6- carbonitrile (compound I), a new potassium channel opener. On-line solid-phase extraction was performed with disposable C18 cartridges. After clean up, the samples were eluted and transferred onto an RP-18 analytical column, where separation was performed with a mobile phase of acetonitrile-10 mM di-n-butylamine phosphate (28:72, v/v). Ultraviolet absorbance detection was used at 236 nm. The detector response was linear in the range 25-2500 ng/ml, and the lowest limit of quantitation was determined at 2.5 ng/ml. The inter-day variability was < 4% for samples at 1000 ng/ml and < 15% for samples at 10 ng/ml. This method was used for the pharmacokinetic study of compound I in rats at three different dosage levels.
建立了一种用于药代动力学研究的全自动反相高效液相色谱法,用于测定新型钾通道开放剂1,2 - 二氢 - 4 - (1,2 - 二氢 - 2 - 氧代 - 1 - 吡啶基)-2,2 - 二甲基 - 1 - 氧代萘 - 6 - 腈(化合物I)的血浆样本。使用一次性C18柱进行在线固相萃取。净化后,将样品洗脱并转移至RP - 18分析柱上,用乙腈 - 10 mM磷酸二正丁胺(28:72,v/v)的流动相进行分离。在236 nm处进行紫外吸光度检测。检测器响应在25 - 2500 ng/ml范围内呈线性,最低定量限为2.5 ng/ml。1000 ng/ml样品的日间变异小于4%,10 ng/ml样品的日间变异小于15%。该方法用于在三种不同剂量水平下对化合物I在大鼠体内的药代动力学研究。